Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC38 | Volasertib | PLK | Cell cycle | 0.0081934 | -0.2598 | 0.6001 | 0.1943 | 3.2088 | 0.0091367 | 0.99678 |
HCC38 | Dinaciclib | pan CDK | Cell cycle | 0.012678 | -0.4422 | 0.6326 | 0.2241 | 4.1199 | 0.014763 | 0.99821 |
HCC38 | Cisplatin | Chemo | Chemotherapy | 0.99272 | -0.1031 | 0.2567 | 0.1098 | 1.4350 | 1.1794 | 0.99675 |
HCC38 | Doxorubicin | Chemo | Chemotherapy | 0.0095452 | -0.4061 | 0.7803 | 0.2872 | 1.4810 | 0.01343 | 0.99228 |
HCC38 | Taxol | Chemo | Chemotherapy | 0.0014659 | -0.3078 | 0.8432 | 0.2758 | 2.3201 | 0.0017274 | 0.99328 |
HCC38 | Topotecan | Topo I | Chemotherapy | 0.0068073 | -0.5041 | 1.0724 | 0.3904 | 1.2181 | 0.011735 | 0.99338 |
HCC38 | Etoposide | Topo II | Chemotherapy | 0.33384 | -0.4242 | 0.4494 | 0.1891 | 1.4384 | 0.50554 | 0.99763 |
HCC38 | Dasatinib | BCR/ABL | MAPK/nRTK | 5.6901 | 0.3322 | 0.1453 | 0.0365 | 0.6048 | 34.9918 | 0.97158 |
HCC38 | Trametinib | MEK | MAPK/nRTK | 0.22023 | 0.1854 | 0.2076 | 0.0234 | 0.6910 | 0.35783 | 0.98881 |
HCC38 | Saracatinib | SRC | MAPK/nRTK | 29.3313 | 0.6139 | 0.1013 | 0.0162 | 0.4862 | 24.1837 | 0.94737 |
HCC38 | ABT-737 | Bcl2/XL | Misc | 0.99805 | -0.4209 | 0.2963 | 0.1000 | 0.9364 | 2.8897 | 0.99657 |
HCC38 | Vorinostat | HDAC | Misc | 0.95999 | -0.2851 | 0.2909 | 0.1227 | 1.6239 | 1.3226 | 0.99701 |
HCC38 | Luminespib | HSP90 | Misc | 0.0071367 | -0.2087 | 0.6295 | 0.1926 | 5.0000 | 0.0076296 | 0.99771 |
HCC38 | A-1210477 | Mcl-1 | Misc | 14.9391 | 0.8870 | 0.0151 | 0.0032 | 4.9989 | 15.3353 | 0.65537 |
HCC38 | Olaparib | PARP | Misc | 8.4247 | 0.4254 | 0.0719 | 0.0230 | 1.0282 | 24.5229 | 0.97772 |
HCC38 | Bleomycin | Radiation | Misc | 0.19854 | -0.2318 | 0.4852 | 0.1896 | 1.1991 | 0.27457 | 0.99721 |
HCC38 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.7055 | 0.1225 | 0.0092 | 1.1410 | 0.22841 | 0.9721 |
HCC38 | Alpelisib | PI3Ka | PI3K/mTOR | 22.4126 | 0.6801 | 0.0440 | 0.0092 | 0.7155 | 102.9667 | 0.92013 |
HCC38 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 2.7028 | 0.0628 | 0.2018 | 0.0249 | 0.6728 | 13.8343 | 0.97542 |
HCC38 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9515 | -0.0246 | 0.0013 | 0.0000 | Inf | -0.17011 |
HCC38 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.01047 | -0.2107 | 0.5383 | 0.0927 | 0.8737 | 0.015621 | 0.99367 |
HCC38 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.4735 | 0.4865 | 0.0140 | 0.0000 | Inf | 0.060078 |
HCC38 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.01911 | -0.0087 | 0.5361 | 0.0402 | 1.3664 | 0.018127 | 0.99621 |
HCC38 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.9760 | -0.0258 | -0.0006 | 0.0000 | Inf | -0.90907 |
HCC38 | Buparlisib | pan PI3K | PI3K/mTOR | 1.2697 | -0.2762 | 0.2554 | 0.0711 | 1.4831 | 1.8745 | 0.99552 |